E-viri
Recenzirano
Odprti dostop
-
Castilla, Jesús; Lecea, Óscar; Martín Salas, Carmen; Quílez, Delia; Miqueleiz, Ana; Trobajo-Sanmartín, Camino; Navascués, Ana; Martínez-Baz, Iván; Casado, Itziar; Burgui, Cristina; Egüés, Nerea; Ezpeleta, Guillermo; Ezpeleta, Carmen
Euro surveillance : bulletin européen sur les maladies transmissibles, 08/2022, Letnik: 27, Številka: 33Journal Article
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
